The present disclosure relates to a bicyclic compound, a pharmaceutical composition thereof, and its novel use. More particularly, the present disclosure relates to the bicyclic compound according to Formula I or Formula II, the pharmaceutical composition for treating a stroke, and the use of the bicyclic compound treating the stroke.

The present invention relates to photochromic indeno fused phenanthrenopyran compounds represented by the following Formula (I). With some embodiments, the photochromic compounds represented by Formula (I) include at least one lengthening group (e.g., R.sup.6 and/or R.sup.7 each independently being a lengthening group) and the compounds of the present invention are photochromicdichroic compounds. The present invention also relates to photochromic compositions and photochromic articles, such as photochromic ophthalmic articles that include one or more photochromic compounds represented by Formula (I). ##STR00001##

The present invention relates to photochromic indeno fused phenanthrenopyran compounds represented by the following Formula (I). With some embodiments, the photochromic compounds represented by Formula (I) include at least one lengthening group (e.g., R.sup.6 and/or R.sup.7 each independently being a lengthening group) and the compounds of the present invention are photochromicdichroic compounds. The present invention also relates to photochromic compositions and photochromic articles, such as photochromic ophthalmic articles that include one or more photochromic compounds represented by Formula (I). ##STR00001##

The invention relates to new types of modulators of the cold menthol receptor TRPM8, to methods of modulating the TRPM8 receptor using these modulators; and in particular the use of the modulators for inducing a sensation of coldness; and also the articles and compositions produced using these modulators.

The invention relates to new types of modulators of the cold menthol receptor TRPM8, to methods of modulating the TRPM8 receptor using these modulators; and in particular the use of the modulators for inducing a sensation of coldness; and also the articles and compositions produced using these modulators.

An object of the present invention is to provide a gardenia blue pigment that exhibits a vivid blue tone that is bright and has reduced redness, and a method for producing the gardenia blue pigment. A gardenia blue pigment that exhibits a vivid blue tone that is bright and has reduced redness is obtained by carrying out the following first and second steps: the first step of reacting at least one peptide selected from the group consisting of soy peptide, sesame peptide, and rice peptide with genipin in a solvent without the supply of a gas containing oxygen; and the second step of treating the reaction solution obtained in the first step with the supply of a gas containing oxygen.

An object of the present invention is to provide a gardenia blue pigment that exhibits a vivid blue tone that is bright and has reduced redness, and a method for producing the gardenia blue pigment. A gardenia blue pigment that exhibits a vivid blue tone that is bright and has reduced redness is obtained by carrying out the following first and second steps: the first step of reacting at least one peptide selected from the group consisting of soy peptide, sesame peptide, and rice peptide with genipin in a solvent without the supply of a gas containing oxygen; and the second step of treating the reaction solution obtained in the first step with the supply of a gas containing oxygen.

Tailored chromatographic media and methods for using the tailored chromatographic media to purify mixtures extracted from cannabis to obtain a cannabinoid having greater than about 90% purity. In an embodiment, the tailored chromatographic media may comprise a porous resin and/or porous carbon and have a surface area of greater than about 900 m2/g, wherein the tailored chromatographic media may further comprise micropores, mesopores, macropores, wherein the tailored chromatographic media may further comprise at least two distributions of macroporous pore sizes, wherein the at least two distributions of macroporous pore sizes may comprise a first population having a macroporous pore size denoted x and a second population having a macroporous pore size denoted y, wherein a ratio of x/y may be about 1:1, and wherein the tailored chromatographic media may further comprise an anionic polysaccharide and a functional moiety.

Tailored chromatographic media and methods for using the tailored chromatographic media to purify mixtures extracted from cannabis to obtain a cannabinoid having greater than about 90% purity. In an embodiment, the tailored chromatographic media may comprise a porous resin and/or porous carbon and have a surface area of greater than about 900 m2/g, wherein the tailored chromatographic media may further comprise micropores, mesopores, macropores, wherein the tailored chromatographic media may further comprise at least two distributions of macroporous pore sizes, wherein the at least two distributions of macroporous pore sizes may comprise a first population having a macroporous pore size denoted x and a second population having a macroporous pore size denoted y, wherein a ratio of x/y may be about 1:1, and wherein the tailored chromatographic media may further comprise an anionic polysaccharide and a functional moiety.

The present disclosure provides a compound of Formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.